ACADIA Pharmaceuticals Correlations
| ACAD Stock | USD 16.54 0.17 1.04% |
The current 90-days correlation between ACADIA Pharmaceuticals and Eliem Therapeutics is -0.07 (i.e., Good diversification). The correlation of ACADIA Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
ACADIA Pharmaceuticals Correlation With Market
Very weak diversification
The correlation between ACADIA Pharmaceuticals and DJI is 0.55 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ACADIA Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
ACADIA |
Moving together with ACADIA Stock
Moving against ACADIA Stock
| 0.67 | TCHH | Trustcash Holdings | PairCorr |
| 0.47 | EQ | Equillium | PairCorr |
| 0.47 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.39 | KZR | Kezar Life Sciences | PairCorr |
| 0.36 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.33 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.4 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.39 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.33 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
Related Correlations Analysis
| -0.02 | 0.86 | -0.55 | 0.8 | -0.68 | ELYM | ||
| -0.02 | -0.17 | 0.1 | 0.11 | -0.01 | HCWB | ||
| 0.86 | -0.17 | -0.54 | 0.7 | -0.58 | SCPH | ||
| -0.55 | 0.1 | -0.54 | -0.39 | 0.51 | MIST | ||
| 0.8 | 0.11 | 0.7 | -0.39 | -0.63 | MCRB | ||
| -0.68 | -0.01 | -0.58 | 0.51 | -0.63 | LUMO | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between ACADIA Stock performing well and ACADIA Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ACADIA Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ELYM | 3.92 | (0.78) | 0.00 | 0.73 | 0.00 | 6.21 | 34.87 | |||
| HCWB | 13.20 | 4.04 | 0.35 | (1.01) | 8.16 | 22.00 | 352.85 | |||
| SCPH | 2.64 | (0.84) | 0.00 | (0.35) | 0.00 | 4.05 | 20.70 | |||
| MIST | 1.90 | 0.19 | 0.12 | 0.24 | 1.61 | 7.19 | 18.66 | |||
| MCRB | 4.93 | 0.19 | 0.02 | 0.60 | 5.66 | 10.84 | 28.84 | |||
| LUMO | 2.44 | 0.38 | 0.06 | (0.43) | 2.72 | 5.95 | 16.25 |
ACADIA Pharmaceuticals Corporate Management
| Parag PharmD | Senior Franchise | Profile | |
| Elizabeth Thompson | Executive Development | Profile | |
| Bob Mischler | Senior Strategy | Profile | |
| Albert Kildani | Senior Communications | Profile | |
| Douglas MD | Executive Development | Profile | |
| James Kihara | Chief VP | Profile |